Search

Ionis Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

59.51 1.54

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

56.36

Max

58.71

Schlüsselkennzahlen

By Trading Economics

Einkommen

-22M

-115M

Verkäufe

22M

268M

EPS

-0.7

Gewinnspanne

-42.787

Angestellte

1,480

EBITDA

-37M

-105M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.1% upside

Dividenden

By Acuity

Nächstes Ergebnis

28. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

214M

9.5B

Vorheriger Eröffnungskurs

57.97

Vorheriger Schlusskurs

59.51

Nachrichtenstimmung

By Acuity

100%

0%

328 / 340 Ranking in Healthcare

Ionis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Aug. 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Monday's close amid broader market weakness and geopolitical tensions.

14. Aug. 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-market trading. No specific news was identified to explain the movement amid broader economic concerns.

13. Aug. 2026, 19:56 UTC

Ionis Pharmaceuticals Inc shares are lower today, reflecting broader market trends. First-time unemployment claims rose, but overall investor sentiment remains stable.

12. Aug. 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

11. Aug. 2026, 23:46 UTC

Ionis Pharmaceuticals shares are higher in after-market trading, reaching a high near the upper end of their one-month range. No specific news was identified.

10. Aug. 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours. Broader market sentiment is cautious following weaker-than-expected labor market data.

7. Aug. 2026, 20:03 UTC

News

Ionis Pharmaceuticals shares are higher today amid increased market volume. HC Wainwright revised Q3 2026 loss estimates, maintaining a "Buy" rating.

6. Aug. 2026, 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

5. Aug. 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

4. Aug. 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

3. Aug. 2026, 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

1. Aug. 2026, 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

31. Juli 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

30. Juli 2026, 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

29. Juli 2026, 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

28. Juli 2026, 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

27. Juli 2026, 20:07 UTC

News
Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

25. Juli 2026, 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

24. Juli 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

23. Juli 2026, 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

22. Juli 2026, 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

21. Juli 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

20. Juli 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Peer-Vergleich

Kursveränderung

Ionis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

54.1% Vorteil

12-Monats-Prognose

Durchschnitt 90.35 USD  54.1%

Hoch 115 USD

Tief 68 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ionis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

16

Buy

3

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat